The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1153
ISSUE 1153
March 31, 2003
Issue 1153
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Adalimumab (Humira) For Rheumatoid Arthritis
March 31, 2003 (Issue: 1153)
Adalimumab (Humira - Abbott), a tumor necrosis factor alpha (TNF-α) inhibitor, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA). A genetically engineered human IgG1 monoclonal antibody, adalimumab is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.